Otsuka/Lundbeck's brexpiprazole data reassure
This article was originally published in Scrip
Otsuka and Lundbeck have released promising new Phase III data for their novel anti-psychotic brexpiprazole just as the US FDA has accepted their NDA for review both as a treatment for schizophrenia and as an adjunctive therapy in major depressive disorder (MDD).
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.